Intercept Pharmaceuticals (NASDAQ:ICPT) Rating Lowered to Market Perform at Raymond James

Intercept Pharmaceuticals (NASDAQ:ICPT) was downgraded by stock analysts at Raymond James from an “outperform” rating to a “market perform” rating in a report released on Monday, The Fly reports.

A number of other equities analysts also recently commented on the company. Robert W. Baird reiterated a “buy” rating and issued a $227.00 price target on shares of Intercept Pharmaceuticals in a research note on Friday, May 22nd. B. Riley reiterated a “buy” rating and issued a $158.00 price target on shares of Intercept Pharmaceuticals in a research note on Friday, May 22nd. Chardan Capital reiterated a “buy” rating and issued a $145.00 price target on shares of Intercept Pharmaceuticals in a research note on Tuesday, May 12th. Oppenheimer downgraded Intercept Pharmaceuticals from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $124.00 to $46.00 in a research note on Monday. Finally, BidaskClub upgraded Intercept Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, April 18th. Eighteen analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $81.48.

Shares of NASDAQ ICPT opened at $47.91 on Monday. Intercept Pharmaceuticals has a 1 year low of $44.50 and a 1 year high of $125.00. The firm has a market cap of $2.55 billion, a price-to-earnings ratio of -4.47 and a beta of 1.82. The company has a debt-to-equity ratio of 10.32, a quick ratio of 4.19 and a current ratio of 4.19. The stock’s 50-day simple moving average is $78.84 and its 200-day simple moving average is $88.09.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported ($2.86) EPS for the quarter, topping the Zacks’ consensus estimate of ($2.94) by $0.08. The business had revenue of $72.60 million during the quarter, compared to the consensus estimate of $69.67 million. Intercept Pharmaceuticals had a negative return on equity of 430.51% and a negative net margin of 127.53%. The company’s revenue for the quarter was up 39.1% compared to the same quarter last year. During the same period last year, the firm earned ($3.03) earnings per share. As a group, research analysts predict that Intercept Pharmaceuticals will post -11.3 EPS for the current year.

In other Intercept Pharmaceuticals news, Director Paolo Fundaro sold 595,578 shares of the business’s stock in a transaction on Wednesday, May 13th. The shares were sold at an average price of $84.60, for a total transaction of $50,385,898.80. Following the completion of the transaction, the director now owns 19,433 shares of the company’s stock, valued at approximately $1,644,031.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last three months, insiders have sold 595,817 shares of company stock valued at $50,405,516. Company insiders own 23.70% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Sarissa Capital Management LP raised its position in shares of Intercept Pharmaceuticals by 34.3% during the first quarter. Sarissa Capital Management LP now owns 1,155,000 shares of the biopharmaceutical company’s stock valued at $72,718,000 after buying an additional 295,000 shares during the last quarter. Macquarie Group Ltd. raised its position in shares of Intercept Pharmaceuticals by 50.5% during the fourth quarter. Macquarie Group Ltd. now owns 545,414 shares of the biopharmaceutical company’s stock valued at $67,588,000 after buying an additional 183,072 shares during the last quarter. Two Sigma Advisers LP raised its position in shares of Intercept Pharmaceuticals by 37.5% during the first quarter. Two Sigma Advisers LP now owns 539,600 shares of the biopharmaceutical company’s stock valued at $33,973,000 after buying an additional 147,200 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Intercept Pharmaceuticals by 6.5% during the first quarter. Geode Capital Management LLC now owns 382,469 shares of the biopharmaceutical company’s stock valued at $24,080,000 after buying an additional 23,187 shares during the last quarter. Finally, Two Sigma Investments LP raised its position in shares of Intercept Pharmaceuticals by 10.6% during the first quarter. Two Sigma Investments LP now owns 333,127 shares of the biopharmaceutical company’s stock valued at $20,974,000 after buying an additional 31,881 shares during the last quarter. 76.46% of the stock is owned by institutional investors and hedge funds.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.

Featured Article: Balanced Fund

The Fly

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.